Skip to Main Content
Skip Nav Destination

Davunetide (generic name for a peptide of eight amino acids, NAPVSIPQ, also known as NAP) is a drug candidate in clinical trials by Allon Therapeutics Inc. (www.allontherapeutics.com). Phase IIa clinical results have shown that davunetide intranasal (AL-108) is safe and well tolerated providing a positive impact on memory function in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer's disease (AD). This chapter describes the discovery of NAP, the active peptide derived from activity-dependent neuroprotective protein (ADNP). The vital roles of ADNP in neuronal development/plasticity are further described. Converging mechanisms including neuroprotection and interaction with the microtubule systems are addressed. The description of the in vivo pharmacology of davunetide (NAP) discloses activity in multiple animal models with highlights on the ADNP-deficient model, the triple transgenic model of Alzheimer's disease and a tau double transgenic mouse model of frontotmporal dementia paving the path to better understanding of neuroprotection and innovative drug discovery and development.

This content is only available via PDF.
You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register

or Create an Account

Close Modal
Close Modal